1. Human bioavailabilty studies;Acocella;Bull. Int. Union Tuberc. Lung Dis.,1989
2. Anonymous, 1999. Panel discussions I, II and III. Int. J. Tuberc. Lung Dis. 3, S317–S321, S351–S352, S381–S387.
3. Availability of quality fixed dose combinations for the treatment of TB: what can we learn from studying the World Health Organization's vaccine model;Blomberg;Int. J. Tuberc. Lung Dis.,1999
4. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid;Boman;Eur. J. Clin. Pharmacol.,1974
5. Mechanism of inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipient, bentonite;Boman;Eur. J. Clin. Pharmacol.,1975